1. Home
  2. MNOV
  3. MNOV News

Latest Medicinova Inc (MNOV) News on September 18, 2025

MediciNova Provides Shareholder Update on Key Developments
MNOV

GlobeNewswire

10 days ago

MediciNova Provides Shareholder Update on Key Developments

MediciNova price target lowered to $5 from $6 at B. Riley
MNOV

TipRanks

3 months ago

MediciNova price target lowered to $5 from $6 at B. Riley

MNOV

Associated Press Finance

4 months ago

MediciNova: Q1 Earnings Snapshot

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
MNOV

Simply Wall St.

5 months ago

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025
MNOV

GlobeNewswire

5 months ago

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients
MNOV

GlobeNewswire

5 months ago

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

US Exchange Penny Stocks To Watch In January 2025
MNOV

Simply Wall St.

8 months ago

US Exchange Penny Stocks To Watch In January 2025

US Penny Stocks To Watch In December 2024
MNOV

Simply Wall St.

9 months ago

US Penny Stocks To Watch In December 2024

MNOV

Zacks Small Cap Research

9 months ago

MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
MNOV

GlobeNewswire

9 months ago

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

MNOV

Zacks Small Cap Research

10 months ago

MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement…

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
MNOV

GlobeNewswire

10 months ago

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver
MNOV

GlobeNewswire

10 months ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

MNOV

Associated Press Finance

10 months ago

MediciNova: Q3 Earnings Snapshot

3 US Penny Stocks With Market Caps Over $40M To Consider
MNOV

Simply Wall St.

10 months ago

3 US Penny Stocks With Market Caps Over $40M To Consider

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis
MNOV

GlobeNewswire

10 months ago

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

MNOV

MT Newswires

a year ago

Top Premarket Gainers

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)
MNOV

GlobeNewswire

a year ago

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago
MNOV

Simply Wall St.

a year ago

MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
MNOV

GlobeNewswire

a year ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

MNOV

Zacks Small Cap Research

a year ago

MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS…

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND
MNOV

GlobeNewswire

a year ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting
MNOV

GlobeNewswire

a year ago

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

MNOV

MT Newswires

a year ago

Sector Update: Health Care Stocks Softer in Afternoon Trading

MNOV

MT Newswires

a year ago

MediciNova Shares Rise as Post-COVID Drug Due to Receive US Patent

MNOV

Zacks Small Cap Research

a year ago

MNOV: Phase 3 ALS Readout in 2025…

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition
MNOV

GlobeNewswire

a year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans
MNOV

Simply Wall St.

a year ago

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
MNOV

GlobeNewswire

a year ago

MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations

FDA panel votes to recommend Eli Lilly's Alzheimer's drug
MNOV

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

MNOV

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit
MNOV

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

MNOV

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
MNOV

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
MNOV

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
MNOV

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
MNOV

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
MNOV

GlobeNewswire

a year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

MNOV

Zacks Small Cap Research

a year ago

MNOV: Multiple Abstracts Presented at 92nd EAS Congress…

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
MNOV

GlobeNewswire

a year ago

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
MNOV

GlobeNewswire

a year ago

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
MNOV

GlobeNewswire

a year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
MNOV

GlobeNewswire

a year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

MNOV

Associated Press Finance

a year ago

MediciNova: Q1 Earnings Snapshot

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
MNOV

GlobeNewswire

a year ago

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years ago
MNOV

Simply Wall St.

a year ago

MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years ago

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
MNOV

GlobeNewswire

a year ago

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
MNOV

GlobeNewswire

a year ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
MNOV

GlobeNewswire

a year ago

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth
MNOV

Simply Wall St.

a year ago

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
MNOV

GlobeNewswire

2 years ago

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…
MNOV

Zacks Small Cap Research

2 years ago

MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…

LifeMD (NASDAQ:LFMD) shareholders have earned a 49% CAGR over the last five years
MNOV

Simply Wall St.

2 years ago

LifeMD (NASDAQ:LFMD) shareholders have earned a 49% CAGR over the last five years

MNOV

Reuters

2 years ago

GLOBAL MARKETS-Stocks slip, yields rise after strong US labor data

Small-cap stocks could outperform in 2024, analyst explains
MNOV

Yahoo Finance Video

2 years ago

Small-cap stocks could outperform in 2024, analyst explains

Riverview Bancorp (RVSB) Q3 Earnings and Revenues Miss Estimates
MNOV

Zacks

2 years ago

Riverview Bancorp (RVSB) Q3 Earnings and Revenues Miss Estimates

MNOV

Associated Press Finance

2 years ago

Riverview Bancorp: Fiscal Q3 Earnings Snapshot

Riverview Bancorp Earns $1.5 Million in Third Fiscal Quarter 2024
MNOV

GlobeNewswire

2 years ago

Riverview Bancorp Earns $1.5 Million in Third Fiscal Quarter 2024

IBN Announces Latest Episode of The Stock2Me Podcast featuring Dr. Alan Baratz, CEO of D-Wave Quantum Inc.
MNOV

GlobeNewswire

2 years ago

IBN Announces Latest Episode of The Stock2Me Podcast featuring Dr. Alan Baratz, CEO of D-Wave Quantum Inc.

Seven Hills Realty Trust Fourth Quarter 2023 Conference Call Scheduled for Wednesday, February 21st
MNOV

Business Wire

2 years ago

Seven Hills Realty Trust Fourth Quarter 2023 Conference Call Scheduled for Wednesday, February 21st

With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors
MNOV

Simply Wall St.

2 years ago

With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors

We Think Applied Therapeutics (NASDAQ:APLT) Needs To Drive Business Growth Carefully
MNOV

Simply Wall St.

2 years ago

We Think Applied Therapeutics (NASDAQ:APLT) Needs To Drive Business Growth Carefully

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
MNOV

GlobeNewswire

2 years ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024
MNOV

PR Newswire

2 years ago

Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024

What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock
MNOV

Zacks

2 years ago

What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock

MNOV

Business Wire

2 years ago

Intevac to Announce Fourth Quarter and Fiscal Year 2023 Results on February 5th

Vuzix Introduces Z100 Smart Glasses to Seamlessly Connect Workers with AI Optimization Tools
MNOV

PR Newswire

2 years ago

Vuzix Introduces Z100 Smart Glasses to Seamlessly Connect Workers with AI Optimization Tools

MNOV

Thomson Reuters StreetEvents

2 years ago

Q2 2024 AngioDynamics Inc Earnings Call

MNOV

Business Wire

2 years ago

Rocky Brands, Inc. to Present at the 2024 ICR Conference

PIMCO Closed-End Funds Declare Monthly Common Share Distributions
MNOV

GlobeNewswire

2 years ago

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Intevac Announces Successful Qualification of TRIO™ System
MNOV

Business Wire

2 years ago

Intevac Announces Successful Qualification of TRIO™ System

H World Group Limited Announces the Change of Officers
MNOV

GlobeNewswire

2 years ago

H World Group Limited Announces the Change of Officers

High Tide to Open First Canna Cabana in Mississauga, Ontario
MNOV

CNW Group

2 years ago

High Tide to Open First Canna Cabana in Mississauga, Ontario

4 Solid Stocks to Buy on Rise in Personal Income, Spending
MNOV

Zacks

2 years ago

4 Solid Stocks to Buy on Rise in Personal Income, Spending

Karuna downgraded, Arm target raised: Wall Street's top analyst calls
MNOV

The Fly

2 years ago

Karuna downgraded, Arm target raised: Wall Street's top analyst calls

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
MNOV

GlobeNewswire

2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Primis Financial Corp. Announces Reauthorization of Stock Repurchase Program
MNOV

PR Newswire

2 years ago

Primis Financial Corp. Announces Reauthorization of Stock Repurchase Program

Investing in Interlink Electronics (NASDAQ:LINK) five years ago would have delivered you a 261% gain
MNOV

Simply Wall St.

2 years ago

Investing in Interlink Electronics (NASDAQ:LINK) five years ago would have delivered you a 261% gain

Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?
MNOV

Zacks

2 years ago

Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
MNOV

GlobeNewswire

2 years ago

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Zepp Health Celebrates 10 Years of Innovation with a Purpose-Led Brand Refresh and Expanded Wellness Healthcare Solutions
MNOV

Business Wire

2 years ago

Zepp Health Celebrates 10 Years of Innovation with a Purpose-Led Brand Refresh and Expanded Wellness Healthcare Solutions

inTEST Continues Executing on Five-Point Strategy to Expand Geographically - Establishes Southeast Asia Center of Excellence in Malaysia
MNOV

Business Wire

2 years ago

inTEST Continues Executing on Five-Point Strategy to Expand Geographically - Establishes Southeast Asia Center of Excellence in Malaysia

Lesaka appoints fintech entrepreneur Ali Mazanderani as Chairman, Kuben Pillay as Lead Independent Director, and Chris Meyer to conclude tenure as Group CEO in February 2024
MNOV

GlobeNewswire

2 years ago

Lesaka appoints fintech entrepreneur Ali Mazanderani as Chairman, Kuben Pillay as Lead Independent Director, and Chris Meyer to conclude tenure as Group CEO in February 2024

inTEST Corporation to Participate in the 12th Annual NYC Summit
MNOV

Business Wire

2 years ago

inTEST Corporation to Participate in the 12th Annual NYC Summit

MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…
MNOV

Zacks Small Cap Research

2 years ago

MNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…

The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitable
MNOV

Simply Wall St.

2 years ago

The past five years for MediciNova (NASDAQ:MNOV) investors has not been profitable

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
MNOV

GlobeNewswire

2 years ago

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Bancroft Fund Ltd. Declares Distribution of $0.32 Per Share
MNOV

GlobeNewswire

2 years ago

Bancroft Fund Ltd. Declares Distribution of $0.32 Per Share

Owning 45% in HireQuest, Inc. (NASDAQ:HQI) means that insiders are heavily invested in the company's future
MNOV

Simply Wall St.

2 years ago

Owning 45% in HireQuest, Inc. (NASDAQ:HQI) means that insiders are heavily invested in the company's future

a.k.a. Brands Holding Corp. (NYSE:AKA) Q3 2023 Earnings Call Transcript
MNOV

Insider Monkey

2 years ago

a.k.a. Brands Holding Corp. (NYSE:AKA) Q3 2023 Earnings Call Transcript

A Look At The Intrinsic Value Of Tredegar Corporation (NYSE:TG)
MNOV

Simply Wall St.

2 years ago

A Look At The Intrinsic Value Of Tredegar Corporation (NYSE:TG)

MNOV

Associated Press Finance

2 years ago

MediciNova: Q3 Earnings Snapshot

Interlink Electronics Reports Third Quarter 2023 Results
MNOV

PR Newswire

2 years ago

Interlink Electronics Reports Third Quarter 2023 Results

MNOV

Associated Press Finance

2 years ago

Aemetis: Q3 Earnings Snapshot

Want $300 in Super-Safe Monthly Dividend Income? Invest $37,800 Into the Following 3 Ultra-High-Yield Stocks
MNOV

Motley Fool

2 years ago

Want $300 in Super-Safe Monthly Dividend Income? Invest $37,800 Into the Following 3 Ultra-High-Yield Stocks

Share on Social Networks: